Cristália invests R $ 160 million

The Brazil produces just 14% of the active principles that are used by the pharmaceutical industry. And part of that percentage is sustained by Cristália laboratory, responsible for producing half of the raw material used in its production. It is with this math based on sustainability between development and production that the company headquartered in Itapira, São Paulo State, invested $ 160 million in new facilities.
Opened this week for the production of active ingredients Oncology (cancer treatment) and peptides (biomolecules), with the presence of President Dilma Rousseff and Sao Paulo Governor Geraldo Alckmin, the unit shall submit their
first results in 2016, with the expansion of the portfolio of the company's active ingredients. "Our goal is to surpass the 50% that we have today. As the results in biotechnology are the long maturation, the initial results should only appear in three years, "assessed Ogari de Castro Pacheco, Cristalia's President.
Today, the active principles of the company, responsible for 50 registered patents, are from, basically, of chemical synthesis. Shareholders ' equity represents 95% of the total applied, with the remaining 5% of Banco Nacional de Desenvolvimento Econômico e Social (BNDES). Executive assessment, investment will prepare the company for a new long-awaited moment for the sector. "The last great boom happened with the arrival of generics at the turn of the century, but
We continue to make the vast majority of medicinal products with active ingredients which are imported. Develop them here is the path to the next big industry cycle, "he adds. The current dependency scenario increases the cost and reduces the breath of domestic industry, according to Pacheco.
The turnover of r $ 1.2 billion last year (an increase of 55% compared to 2011) is the result of diversified positioning on four fronts on which retailers represents only a small portion. "Our focus is the hospital sector, sales of active principles for industry and the PDP (Productive partnerships for development)". Only the Cristália is responsible for almost half of PDPs that transfer technology to the public laboratories (24 of 54 in force today).
One of these partners, for example, is the Fiocruz in Rio de Janeiro, which produces the Imatinib mesylate. The drug is indicated for the treatment of chronic myeloid leukemia (CML) and intestinal stromal (tumour of the intestine). In this model, which replaces the acquisition of international patents, the public purse will save more than $ 300 million by 2017.